Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives $18.80 Consensus Target Price from Analysts
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average […]
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) have received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average […]
